Valuation: Theralase Technologies Inc.

Market Cap 79.83M 56.97M 49.49M 45.95M 42.38M 5.44B 81.28M 544M 213M 2.7B 214M 209M 9.08B P/E 2026 *
-27x
P/E 2027 * 13.5x
Enterprise Value 79.83M 56.97M 49.49M 45.95M 42.38M 5.44B 81.28M 544M 213M 2.7B 214M 209M 9.08B EV / Sales 2026 *
99.5x
EV / Sales 2027 * 2.36x
Free-Float
87.46%
Yield 2026 *
-
Yield 2027 * -
1 day+3.70%
1 week+7.69%
Current month+9.80%
1 month+9.80%
3 months-12.50%
6 months+12.00%
Current year+69.70%
1 week 0.26
Extreme 0.26
0.29
1 month 0.25
Extreme 0.25
0.29
Current year 0.16
Extreme 0.16
0.41
1 year 0.14
Extreme 0.145
0.41
3 years 0.14
Extreme 0.14
0.41
5 years 0.14
Extreme 0.14
0.48
10 years 0.12
Extreme 0.12
0.6
Manager TitleAgeSince
Chief Executive Officer - 29/06/2023
Director of Finance/CFO - 27/06/2019
Chief Executive Officer - 15/11/2021
Director TitleAgeSince
Chairman - -
Director/Board Member - 01/01/2008
Director/Board Member - 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
20/05/26 Buy

Director

20,900 0.0081%
20/05/26 Option

Chief Financial Officer

11,000 0.0043%
31/07/25 Sell

Chief Financial Officer

130,000 0.0525%
Change 5-day change 1-year change 3-year change Capi.($)
+3.70%+7.69%+33.33%-1.75% 56.66M
+4.24%+1.68%+31.03%+45.97% 1.38B
+1.87%+0.93%-12.66%-49.18% 51.74M
Average +3.27%-1.86%+17.23%-1.66% 495.54M
Weighted average by Cap. +4.14%-4.62%+29.60%+40.84%

Financials

2026 *2027 *
Net sales 802K 572K 497K 462K 426K 54.64M 817K 5.47M 2.14M 27.14M 2.15M 2.1M 91.26M 33.89M 24.18M 21.01M 19.51M 17.99M 2.31B 34.5M 231M 90.42M 1.15B 90.82M 88.83M 3.86B
Net income -4.2M -3M -2.6M -2.42M -2.23M -286M -4.28M -28.62M -11.21M -142M -11.26M -11.01M -478M 6.83M 4.88M 4.23M 3.93M 3.63M 465M 6.95M 46.55M 18.23M 231M 18.31M 17.91M 777M
Net Debt - -
Logo Theralase Technologies Inc.
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Employees
20
Date Price Change Volume
30/07/26 CA$0.2800 +3.70% 109,511
29/07/26 CA$0.2700 0.00% 223,068
28/07/26 CA$0.2700 +3.85% 43,002
27/07/26 CA$0.2600 -1.89% 18,519
24/07/26 CA$0.2650 +1.92% 79,502
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2700CAD
Average target price
0.7000CAD
Spread / Average Target
+159.26%

Quarterly revenue - Rate of surprise